Cellectis to Collaborate with France's INRA | GenomeWeb

NEW YORK (GenomeWeb News) – French genome engineering company Cellectis said yesterday that it will collaborate with the French National Institute for Agricultural Research, or INRA, to investigate the use of Cellectis' technology in a range of applications.

Under the five-year, non-exclusive agreement, Cellectis and INRA will investigate the potential of a range of technologies in which Cellectis specializes, including reverse genetics, homologous recombination, and gene targeting, in applications such as cell biology and plant and animal biotechnology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.